mycamine
Fujisawa Healthcare, Inc mycamine. Submits NDA For Mycamine For Treatment Of EsophagealCandidiasis
Deerfield, Ill., April 27, 2004-- Fujisawa Healthcare, Inc mycamine. (Fujisawa) announcedtoday that a New Drug Application (NDA) has been submitted to the U.S mycamine. Foodand Drug Administration (FDA) for their investigational antifungal product tobe marketed in the U.S mycamine. under the name Mycamine (micafungin sodium) mycamine. With thesubmission of the NDA, Fujisawa seeks approval of micafungin for the treatmentof esophageal candidiasis. Micafungin is a member of a new class of antifungal agents, the echinocandins,which inhibit cell-wall synthesis mycamine. The novel mechanism of action of echinocandinsspecifically targets the wall of fungal cells to treat the infection. About Esophageal Candidiasis
Esophageal candidiasis is a fungal infection located deep below the throat mycamine. It is most commonly seen in immuno-compromised patients mycamine. Approximately 10% ofthe U.S mycamine. AIDS population will have at least one episode of esophageal candidiasis mycamine. Symptoms of esophageal candidiasis can include chest pains and difficulty swallowing mycamine. Treating the presence of candidiasis in the esophagus, before it moves pastthe gastrointestinal tract, is key in arresting the progress of the fungus beforeit reaches more difficult to treat areas such as the lungs, bloodstream andkidney. About Fujisawa Healthcare, Inc.
Fujisawa Healthcare, Inc., headquartered in Deerfield, Ill., develops, manufactures,and markets proprietary pharmaceutical products in the United States and abroad mycamine. Fujisawa Healthcare, Inc mycamine. is a subsidiary of Fujisawa Pharmaceutical Co., Ltd mycamine. based in Osaka, Japan mycamine. Fujisawa Pharmaceutical Co., Ltd., founded in 1894, isa leading pharmaceutical manufacturer and is actively developing its internationaloperations in North America, Europe, and Asia mycamine. Fujisawa Healthcare, Inc mycamine. establishedits presence in the anti-fungal market with the launch of AmBisome (liposomalamphotericin B) in 1997.
|
